[Response of fetal macrophages in the placenta of pregnant HIV-positive patients with and without antiretroviral treatment].
We studied the cellular answer of placentary macrophages in pregnant women seropositive to the virus of human immunodefficiency (VIH-1) treated with zidovudina (AZT) and didanosine (ddl). Twenty eight pregnant women were studies; there were four groups of seven patients each: The control group; the group with seropositive women without treatment; the group given AZT, and the group that recieved AZT and ddl. Placentary specimens were obtained immediately after delivery. One hundred and fifty chorionic vellosities of cells. The control group showed an average of 26 Hofbauer cells; the seropositive women without antiretroviral treatment, was 115; the patients who received only AZT, the average was 65; and the ones who received a combine therapy AZT and ddl, cellular average was 44. There were no differences in the weight of the products in all the groups, nor congenital malformations in the newborns. The use of medication antiretroviral suppress viral replication, and so, there is a significant answer in the amount and size of Hofbauer cells. The administration of two medicaments is more effective in the cellular immune answer.
Villegas Castrejón
H
H
Departamento de Microscopia Electrónica, Instituto Nacional de Perinatología, Méx. D.F.
Mayón González
J
J
Paredes Vivas
Y
Y
Karchmer
S
S
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016049:Didanosine / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D006679:HIV Seropositivity; D006801:Humans; D008264:Macrophages / Q000187:drug effects; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000821:virology*; D012190:Retroviridae / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use*
D000998:Antiviral Agents; D015215:Zidovudine; D016049:Didanosine
Respuesta de los macrófagos fetales en placentas de pacientes embarazadas VIH-1 positivas con tratamiento y sin tratamiento antiretroviral.